Market Cap 1.42B
Revenue (ttm) 70.85M
Net Income (ttm) -342.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -483.56%
Debt to Equity Ratio 0.07
Volume 1,052,600
Avg Vol 2,245,186
Day's Range N/A - N/A
Shares Out 103.07M
Stochastic %K 10%
Beta 1.16
Analysts Strong Sell
Price Target $33.44

Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 272 4600
Fax: 617 272 4601
Address:
221 Crescent Street, Suite 103A, Waltham, United States
PotatoJenkins
PotatoJenkins Apr. 24 at 8:58 PM
$VRDN keep dropping the price, so I can buy more shares!!!🐂🐂🐂
0 · Reply
SirBioAlot
SirBioAlot Apr. 24 at 7:10 PM
$VRDN this is normal. seen it countless times before bios rip. price doesn’t reflect the potential right now, but this turns overnight and when it does this board will be on fire. everyone accumulating here is positioned ahead of the folks who bought before the first and second drop. that’s a hell of a starting point. two catalysts in 10 weeks. REVEAL-2 then veligrotug PDUFA June 30. $875M cash. RSI 25. sitting near 52w low. the setup is textbook. patience pays. loaded and chilling.​​​​​​​​​​​​​​​​
1 · Reply
CDMO
CDMO Apr. 24 at 3:58 PM
$VRDN $IDYA added both
2 · Reply
HamBoneXoXo
HamBoneXoXo Apr. 23 at 5:37 PM
$VRDN IMHO, this is just a matter of time ticker. Only the patients and patience will be awarded.
0 · Reply
SirBioAlot
SirBioAlot Apr. 21 at 8:57 PM
$VRDN REVEAL-2 read-through nobody talks about. elegrobart shares the exact same IGF-1R binding domain as veligrotug, literally engineered from it with half-life extension for SC. same target, same biology. veligrotug THRIVE-2 in chronic TED crushed it. 56% PRR vs 8% placebo, 48% placebo-adj, p<0.0001. first ph3 ever to work in chronic TED. REVEAL-1 tested active (easier pop where veligrotug was only solid), that’s why 36/45% placebo-adj disappointed. REVEAL-2 tests chronic, exactly where this binding crushed it. mgmt flagged the read-through themselves. catalysts stacking. REVEAL-2 topline Q2 in 6-8 weeks. veligrotug PDUFA June 30, priority review, breakthrough, ~85% PoA. EMA MAA Q1. mid-2026 US launch into $2B market. $14.23 near 52w low $11.76. RSI 25 oversold. $875M cash, runway to profitability. everyone anchored on REVEAL-1 pain, nobody pricing REVEAL-2 could beat it AND veligrotug approved 10 weeks later. asymmetric af. Not financial advice
2 · Reply
Tdorsey1776
Tdorsey1776 Apr. 21 at 1:35 PM
$VRDN "Viridian is considered by some analysts as one of the most oversold healthcare stocks to invest in during this period" Truist BUY with $33 revised
0 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Apr. 20 at 3:20 PM
$VRDN can someone help explain why the stock dropped quite a bit in the last month? Thank you
1 · Reply
BioTechHealthX
BioTechHealthX Apr. 19 at 2:41 AM
$VRDN Viridian Therapeutics is taking aim at thyroid eye disease with late-stage therapies that could rival existing treatments. With strong clinical data and solid cash reserves, this biotech stock is gaining serious traction. https://biotechhealthx.com/biotech-news/would-you-still-dare-to-invest-in-viridian-therapeutics-vrdn/
0 · Reply
SirBioAlot
SirBioAlot Apr. 18 at 2:48 PM
$VRDN if approved the setup is compelling. EV ex-cash is only ~$460M for a $2B market where the only competitor is drowning in 270 MDL hearing loss lawsuits. veligrotug showed lower hearing imp. rates than tepezza and ele printed zero clinical hearing loss in REVEAL-1. not a minor edge in today’s liability environment. march 30 crash candle printed 23M volume at RSI 22, textbook capitulation. volume cluster $18-21 acts as a magnet and we’re entering the pre-PDUFA window where these names start moving. honestly $22-25 is the realistic first stop — 38-50% fib and the gap zone. $28 gets heavy, loaded with people who bought $25-30 before the crash. $28-35 possible in a strong scenario but not base case. if CRL the $12 cash floor is real. $875M plus kissei and DRI deals confirm pipeline value regardless. brutal day down 35-45% but buyers step in at $12-13. only breaks if CRL flags a data gap not labeling. asymmetric. risking $3-4 to make $8-12 with a hard catalyst date. not financial advice
1 · Reply
SirBioAlot
SirBioAlot Apr. 17 at 11:13 AM
$VRDN still pretty quiet here — and that’s exactly how it always goes. the ones who are here now loaded up early. the rest usually chases the price. StockTwits fills up 4-6 weeks before PDUFA when the stock has already accumulated and people buy in too high. saw it with $RCKT, $VNDA, $KURA and plenty others. so if you’re reading this now — you’re early. enjoy it while it lasts. not financial advice
1 · Reply
Latest News on VRDN
Why Is Viridian Therapeutics Stock Sinking Monday?

Apr 6, 2026, 1:41 PM EDT - 20 days ago

Why Is Viridian Therapeutics Stock Sinking Monday?


Why Is Viridian Therapeutics Stock Falling Monday?

Mar 30, 2026, 10:01 AM EDT - 27 days ago

Why Is Viridian Therapeutics Stock Falling Monday?


Viridian Therapeutics Transcript: Study result

Mar 30, 2026, 8:00 AM EDT - 27 days ago

Viridian Therapeutics Transcript: Study result


Viridian Therapeutics Prepares for Transformational 2026

Jan 6, 2026, 7:01 AM EST - 3 months ago

Viridian Therapeutics Prepares for Transformational 2026


Top 3 Health Care Stocks You May Want To Dump This Quarter

Jul 30, 2024, 10:13 AM EDT - 1 year ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRNA


Viridian Therapeutics Earnings Call Transcript: Q1 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Earnings Call Transcript: Q1 2024


Viridian Therapeutics Transcript: Study Update

Dec 18, 2023, 8:00 AM EST - 2 years ago

Viridian Therapeutics Transcript: Study Update


Viridian Therapeutics Transcript: Study Result

Jul 10, 2023, 5:00 PM EDT - 3 years ago

Viridian Therapeutics Transcript: Study Result


Viridian Therapeutics Earnings Call Transcript: Q1 2023

May 9, 2023, 4:30 PM EDT - 3 years ago

Viridian Therapeutics Earnings Call Transcript: Q1 2023


Viridian Therapeutics Earnings Call Transcript: Q4 2022

Mar 8, 2023, 8:00 AM EST - 3 years ago

Viridian Therapeutics Earnings Call Transcript: Q4 2022


Viridian Therapeutics Earnings Call Transcript: Q3 2022

Nov 14, 2022, 8:00 AM EST - 3 years ago

Viridian Therapeutics Earnings Call Transcript: Q3 2022


Viridian Therapeutics Earnings Call Transcript: Q2 2022

Aug 15, 2022, 8:00 AM EDT - 4 years ago

Viridian Therapeutics Earnings Call Transcript: Q2 2022


Viridian Therapeutics Earnings Call Transcript: Q1 2022

May 12, 2022, 4:30 PM EDT - 4 years ago

Viridian Therapeutics Earnings Call Transcript: Q1 2022


Viridian Therapeutics Earnings Call Transcript: Q4 2021

Mar 10, 2022, 4:30 PM EST - 4 years ago

Viridian Therapeutics Earnings Call Transcript: Q4 2021


Viridian Therapeutics Transcript: AGM 2021

Jun 3, 2021, 12:00 PM EDT - 5 years ago

Viridian Therapeutics Transcript: AGM 2021


PotatoJenkins
PotatoJenkins Apr. 24 at 8:58 PM
$VRDN keep dropping the price, so I can buy more shares!!!🐂🐂🐂
0 · Reply
SirBioAlot
SirBioAlot Apr. 24 at 7:10 PM
$VRDN this is normal. seen it countless times before bios rip. price doesn’t reflect the potential right now, but this turns overnight and when it does this board will be on fire. everyone accumulating here is positioned ahead of the folks who bought before the first and second drop. that’s a hell of a starting point. two catalysts in 10 weeks. REVEAL-2 then veligrotug PDUFA June 30. $875M cash. RSI 25. sitting near 52w low. the setup is textbook. patience pays. loaded and chilling.​​​​​​​​​​​​​​​​
1 · Reply
CDMO
CDMO Apr. 24 at 3:58 PM
$VRDN $IDYA added both
2 · Reply
HamBoneXoXo
HamBoneXoXo Apr. 23 at 5:37 PM
$VRDN IMHO, this is just a matter of time ticker. Only the patients and patience will be awarded.
0 · Reply
SirBioAlot
SirBioAlot Apr. 21 at 8:57 PM
$VRDN REVEAL-2 read-through nobody talks about. elegrobart shares the exact same IGF-1R binding domain as veligrotug, literally engineered from it with half-life extension for SC. same target, same biology. veligrotug THRIVE-2 in chronic TED crushed it. 56% PRR vs 8% placebo, 48% placebo-adj, p<0.0001. first ph3 ever to work in chronic TED. REVEAL-1 tested active (easier pop where veligrotug was only solid), that’s why 36/45% placebo-adj disappointed. REVEAL-2 tests chronic, exactly where this binding crushed it. mgmt flagged the read-through themselves. catalysts stacking. REVEAL-2 topline Q2 in 6-8 weeks. veligrotug PDUFA June 30, priority review, breakthrough, ~85% PoA. EMA MAA Q1. mid-2026 US launch into $2B market. $14.23 near 52w low $11.76. RSI 25 oversold. $875M cash, runway to profitability. everyone anchored on REVEAL-1 pain, nobody pricing REVEAL-2 could beat it AND veligrotug approved 10 weeks later. asymmetric af. Not financial advice
2 · Reply
Tdorsey1776
Tdorsey1776 Apr. 21 at 1:35 PM
$VRDN "Viridian is considered by some analysts as one of the most oversold healthcare stocks to invest in during this period" Truist BUY with $33 revised
0 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Apr. 20 at 3:20 PM
$VRDN can someone help explain why the stock dropped quite a bit in the last month? Thank you
1 · Reply
BioTechHealthX
BioTechHealthX Apr. 19 at 2:41 AM
$VRDN Viridian Therapeutics is taking aim at thyroid eye disease with late-stage therapies that could rival existing treatments. With strong clinical data and solid cash reserves, this biotech stock is gaining serious traction. https://biotechhealthx.com/biotech-news/would-you-still-dare-to-invest-in-viridian-therapeutics-vrdn/
0 · Reply
SirBioAlot
SirBioAlot Apr. 18 at 2:48 PM
$VRDN if approved the setup is compelling. EV ex-cash is only ~$460M for a $2B market where the only competitor is drowning in 270 MDL hearing loss lawsuits. veligrotug showed lower hearing imp. rates than tepezza and ele printed zero clinical hearing loss in REVEAL-1. not a minor edge in today’s liability environment. march 30 crash candle printed 23M volume at RSI 22, textbook capitulation. volume cluster $18-21 acts as a magnet and we’re entering the pre-PDUFA window where these names start moving. honestly $22-25 is the realistic first stop — 38-50% fib and the gap zone. $28 gets heavy, loaded with people who bought $25-30 before the crash. $28-35 possible in a strong scenario but not base case. if CRL the $12 cash floor is real. $875M plus kissei and DRI deals confirm pipeline value regardless. brutal day down 35-45% but buyers step in at $12-13. only breaks if CRL flags a data gap not labeling. asymmetric. risking $3-4 to make $8-12 with a hard catalyst date. not financial advice
1 · Reply
SirBioAlot
SirBioAlot Apr. 17 at 11:13 AM
$VRDN still pretty quiet here — and that’s exactly how it always goes. the ones who are here now loaded up early. the rest usually chases the price. StockTwits fills up 4-6 weeks before PDUFA when the stock has already accumulated and people buy in too high. saw it with $RCKT, $VNDA, $KURA and plenty others. so if you’re reading this now — you’re early. enjoy it while it lasts. not financial advice
1 · Reply
HamBoneXoXo
HamBoneXoXo Apr. 16 at 6:00 PM
$VRDN Ton of tomorrow puts at 12-15. So the battle is $15 at least till tomorrow 4 pm est.
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 16 at 4:20 AM
$VRDN Viridian Therapeutics (NASDAQ: VRDN) is entering a critical stage where late-stage clinical results could reshape its valuation overnight. With a strong cash position and a focused pipeline in thyroid eye disease, is this biotech finally nearing its breakout moment? https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-buy-viridian-therapeutics-vrdn-shares/
0 · Reply
Cmon11
Cmon11 Apr. 15 at 3:37 PM
$VRDN Interesting how Vanguard timed their exit of 3m shares right before the 3/30 news
0 · Reply
HamBoneXoXo
HamBoneXoXo Apr. 14 at 2:46 PM
$VRDN Are we $18 yet? If not today may be tomorrow. Back to fishing…
0 · Reply
SecoTrader
SecoTrader Apr. 14 at 10:47 AM
$VRDN this is up 7.5% premarket to nearly 16$…some news on the horizon??
0 · Reply
bxlams
bxlams Apr. 13 at 1:06 PM
$VRDN & $VERA adding this two soon
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 12 at 5:57 AM
$ADMA $CRMD $EYPT $URGN $VRDN Looking for high-risk, high-reward biotech stocks? These top 5 microcap biotech companies are positioned for major breakthroughs that could drive significant upside for early investors. https://biotechhealthx.com/biotech-news/top-5-microcap-biotech-stocks-that-could-multiply-your-money-fast/
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 12 at 2:52 AM
$EYPT $LQDA $OCGN $URGN $VRDN The biotech sector is heating up again. These top 5 best microcap biotech stocks are gaining traction with strong pipelines, upcoming trial results, and serious upside potential investors shouldn’t ignore. https://biotechhealthx.com/biotech-news/top-5-best-microcap-biotech-stocks-that-could-explode-10x-in-2026/
0 · Reply
SirBioAlot
SirBioAlot Apr. 10 at 5:35 PM
$VRDN let’s take a step back. the stock took every hit imaginable in two weeks. -40% crash on phase 3 data. amgen SC news. iran war. risk-off over easter. yet: $12 cash floor holds. veligrotug PDUFA june 30 unchanged. REVEAL-2 still coming. ceasefire has removed the biggest macro pressure for now. and amgen is sitting on 270+ MDL lawsuits over tepezza hearing loss — not viridian. the market punished viridian as if the story is over. nothing has changed on the FDA decision for veligrotug. breakthrough therapy. priority review. both phase 3 trials hit all endpoints. risks are real: ceasefire lasts only two weeks and can fall apart anytime. REVEAL-2 could disappoint. a CRL on june 30 is not impossible. for me the positives outweigh the risks — but everyone has to make that call themselves. not financial advice
0 · Reply
HamBoneXoXo
HamBoneXoXo Apr. 9 at 7:41 PM
$VRDN If into options, I find selling 14 and 15 puts generating good enough money to pay for the $4 gas
0 · Reply
HamBoneXoXo
HamBoneXoXo Apr. 9 at 7:39 PM
$VRDN No one mentioned that we are up 6%. 🍾🕺
0 · Reply
MaverikIT
MaverikIT Apr. 9 at 5:27 PM
2 · Reply